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Accepted 2 October 2012AbstractObjective: The aim of this study was to investigate the validity of the risk of malignancy index (RMI) in premenopausal and postmenopausal
patients with adnexal masses.
Materials and Methods: The study involved all women treated for adnexal tumors throughout an 18-month period in the Clinic for Gynecology
and Obstetrics, Clinical Center of Serbia (Belgrade, Serbia). On admission, detailed anamnestic and laboratory data were obtained and an expert
ultrasound scan was performed. The RMI was calculated for all patients and the obtained data were related to histopathological findings of the
tumors. For statistical analysis, we used descriptive and analytical statistics methods and an SPSS computer program.
Results: From a total number of 540 women, 85 women had malignant tumors; 20 women, borderline tumors; and 435 women, benign adnexal
tumors. The RMI was reliable in 84.6% of all patients; in 77% of premenopausal patients, and in 81.1% of postmenopausal patients. The
sensitivity of the RMI in the overall population was 83.81%; the specificity was 77.24%; the positive predictive value (PPV) was 47.06%, and the
negative predictive value (NPV) was 95.18%. In premenopausal women, the RMI sensitivity was 83.87%; specificity, 80.31%; PPV, 28.89%; and
NPV, 98.12%. In postmenopausal women the RMI sensitivity was 83.78%; specificity, 68.18%; PPV, 63.92%; and NPV, 74.71%.
Conclusion: TheRMIwas a reliable factor for differentiating benign frommalignant adnexalmasses in premenopausal and postmenopausal patients.
Copyright 2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Gynecologic malignancies from ovarian cancer remain a
leading cause of death [1]. More than two-thirds of ovarian
cancer cases are diagnosed when the disease has progressed to
stage III or IV and has involved the peritoneal cavity or other
organs [2]. Symptoms that are associated with ovarian cancer
are typically nonspecific and the association is often not
recognized until the disease has advanced. Therefore,* Corresponding author. Clinic of Ob/Gyn, Medical Faculty, University of
Belgrade, Dr Koste Todorovica 26, 11000 Belgrade, Serbia.
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http://dx.doi.org/10.1016/j.tjog.2013.04.017recognizing it at the early stage is of utmost importance.
However, several features of ovarian cancer complicate its
screening. Two-thirds of ovarian cancer cases are diagnosed in
women over the age of 55 years [3]. The validity of the risk of
malignancy index (RMI) in postmenopausal patients is well
known and widely accepted. Its role in premenopausal patients
remains undefined [3]. Furthermore, in recent years the inci-
dence of ovarian cancer is increasing in younger women. The
aim of this study was to verify the validity of RMI in
discriminating between benign and malignant adnexal masses
in clinical practice and to compare its value in premenopausal
and postmenopausal women.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1







Age Mean 53.44 37.12 61.73
SD 16.82 9.10 9.42
Minimum 18 18 35
Maximum 82 61 82
RMI Mean 3065.53 212.67 2117.39
SD 9171.38 697.27 6754.90
Minimum 0.00 0.00 0.00
Maximum 61305.00 8434.00 61305.00
RMI ¼ risk of malignancy index; SD ¼ standard deviation.
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The study included all consecutive patients who had un-
dergone surgery for adnexal tumors at the Clinic of Gyne-
cology and Obstetrics, Clinical Center of Serbia (Belgrade,
Serbia) during an 18-month period (July 1, 2010 to December
31, 2011). Written, informed consent was obtained from all
patients for all necessary diagnostic methods, for surgery, and
for inclusion into this study. On admission, all women un-
derwent detailed anamnesisdespecially in regard to the time
of the last menstrual cycledand all standard laboratory ana-
lyses (e.g., blood analysis, the CA-125 level as a tumor
marker). Furthermore, expert clinical and ultrasound exami-
nations were performed of the abdominal and pelvic organs
(e.g., tumor diameter, multilocularity and bilaterality, solid/
cystic components/parts, metastases and presence of ascites).
The RMI was calculated for all patients by using the following
formula: RMI ¼ U  M  CA-125. In the formula, U rep-
resents the ultrasonographic index. Multilocular and bilateral
tumors, the presence of solid parts in a tumor, metastasis and
ascites are each marked with one point. The sum of these
points, are scored so that in the formula U 0 ¼ 0 points, U
1 ¼ 1 point, and U 2e5 ¼ 3 points. In the formula M repre-
sents menopausal status (1 for premenopausal and 3 for
postmenopausal women). The CA-125 level is calculated
directly into the equation. The patients were divided into three
groups, according to the RMI values (low risk less than 25,
intermediate risk 25e250, and high risk greater than 250).
After surgery and the removal of the adnexal masses, the
histopathological (HP) findings were analyzed to make a final
diagnosis and determine the stage of the disease. After
obtaining the HP verification of the tumor type and a specific
diagnosis, the following were calculated: (1) sensitivity [i.e.,
(true positive/true positive þ false negative)  100]; (2)
specificity [i.e., (true negative/true negative þ false
positive)  100]; (3) positive predictive value [(true positive/
true positive þ false positive)  100]; and (4) negative pre-
dictive value [(true negative/true negative þ false
negative)  100]. The receiver operating characteristic (ROC)
curves were then established for premenopausal and post-
menopausal women, and for the whole population of the
examined patients.
For statistical analysis of the achieved data we used
descriptive statistics methods, the Kolmogorov-Smirnov Z
test, Friedman’s parametric ANOVA, the c2 test and threshold
analysis. Data of the descriptive parameters were expressed as
the mean  the standard deviation and the range, unless stated
otherwise. For data analysis, an SPSS 15 computer program
was used.
Results
The study involved 540 women. Of these, 356 were of
reproductive age and 184 were in menopause. Malignancy was
histopathologically present in 85 women, borderline tumors
were present in 20 women, and benign tumors were present in
435 patients.Table 1 shows the average age of the examined patients.
High significant differences existed between the tumor types
in regard to the woman’s age (F ¼ 41.999, p < 0.001). The
youngest group was women with benign tumors. There were
no significant differences between women with malignant
tumors and women with borderline tumors. Most women with
benign tumors were 30e39 years old, whereas most women
with malignant or borderline tumors were 50e59 years old.
The highest RMI levels were in women 50e59 years old and
the lowest levels were in women younger than 19 years old
(c2 ¼ 55.401, p < 0.001). A high risk for malignancy was
more frequent in postmenopausal women, whereas low and
intermediate risks were more usual in premenopausal women
(F ¼ 27.781, p < 0.001).
Table 1 presents the RMI levels of all examined women and
in the groups of premenopausal and postmenopausal patients.
Table 2 presents the number of patients in each risk categories
(i.e., low, intermediate, and high), based on their RMI level.
There were significantly large differences between the
tumor types in regard to the patients’ RMI (for the overall
examined population, F ¼ 40.692 and p < 0.001; for post-
menopausal women, F ¼ 13.182 and p < 0.001; for premen-
opausal women, F ¼ 24.158 and p < 0.001). The RMI values
were significantly greater in women with malignant tumors
than in women with other tumor types in all three examined
populations. There were no significant differences between
women with benign tumors and women with borderline tu-
mors in all three examined populations (i.e., all, post-
menopausal, and premenopausal women).
The RMI was reliable for 84.6% of all patients. In the
examined postmenopausal patients, the RMI was accurate for
81.1% of the women, whereas the RMI was accurate for 77%
of premenopausal women (Fig. 1). Table 3 presents the
sensitivity and specificity of the RMI on cutoff at the recom-
mended intermediate risk level of 25 and high risk level of
250. Furthermore, we assessed other cutoff points with a better
sensitivity/specificity ratio obtained from the receiver oper-
ating characteristic (ROC) analysis. The RMI cutoff point of
29.6 had a sensitivity of 94.1% and a specificity of 29.7%. The
RMI cutoff point of 107.4 had a sensitivity of 80.0% and a
specificity of 70.3%. The RMI cutoff point of 204.2 had a
sensitivity of 72.9% and a specificity of 84.8%. For premen-
opausal women, the most appropriate sensitivity/specificity
Table 2







Low 123 108 15
Intermediate 285 196 89
High 132 52 80
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and a specificity of 72%.
By evaluating the relationships between RMI and HP in the
examined populations, we have established the number of
true-positive, false-positive, false-negative, and true-negative
findings. From these values, the sensitivity, specificity, posi-
tive predictive value (PPV), and negative predictive value
(NPV) of the RMI were calculated for the overall population,
premenopausal women, and postmenopausal women. Table 4
presents these findings.Discussion
Of all gynecological malignancies, ovarian cancer gener-
ally has the worst prognosis since it is usually diagnosed at an
advanced stage [4]. A definitive diagnosis of ovarian cancer
can be established as a rule only after surgery [5,6]. To detect
the disease at a very early stage, several approaches have been
used to triage women with suspicious ovarian tumors. These
attempts include using a single cutoff for the serum CA-125
titer, ultrasonic morphology scoring systems, Doppler ultra-
sonic parameters, and complex statistical models developed
from multivariate logistic regression [7,8].
According to the referral guidelines, for a newly diagnosed
ovarian mass, patients are stratified on the basis of the wom-
an’s menopausal status. Women in menopause, a CA-125 level
greater than 200 U/mL, the presence of ascites, evidence of
abdominal or distant metastasis (by examination or imaging
study) are usual indications for referral to gynecological on-
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Fig. 1. The risk of malignancy index receiver operating characteristic (ROC)
curves for the examined populations. RMI ¼ risk of malignancy index.independently associated with the likelihood of malignancy
[7,9]. However, none of these parameters examined alone have
proven its accuracy in predicting the nature of the adnexal
tumor. The risk of malignancy index incorporates all these
parameters and is used to predict the likelihood of malignancy
in patients presenting with an ovarian mass. The RMI (which
is based on menopausal status), ultrasound findings, and serum
CA-125 level are the most widely used methods for preoper-
atively differentiating between malignant and benign diseases
[10,11]. The effectiveness of the RMI has also been validated
in a number of studies, and has been proven as a simple, low-
cost, and effective tool for triage and for managing ovarian
masses in postmenopausal women [7,12].
The sensitivity of the RMI shows that is it able to label
malignant tumors in high-risk cases, whereas its specificity
shows it is able to label benign tumors as low-risk cases. The
best result is when all examined parameters (i.e., sensitivity,
specificity, PPV, and NPV) are high, but it is more important if
the test has a high sensitivity. It is expected that specificity of
the RMI would be lower than sensitivity since unreferred
benign cases are not detected [7]. Our results were consistent
with the expected lower specificity of the RMI in all three
examined groups (i.e., overall population, premenopausal
women, and postmenopausal women).
Numerous previous reports have tested the sensitivity and
specificity of different RMI cutoff values in the overall popu-
lation of women with adnexal masses. Most studies found the
RMI had a high specificity when using a cutoff value of 25, 200,
or 250 [7]. In available literature data, a cutoff level of 25 ach-
ieves a sensitivity of 98% and a specificity of 42%; this indicates
that 98% of ovarian cancer cases have a RMI of more than 25
[10]. The results of our study for overall patients
(sensitivity ¼ 83.81%, specificity ¼ 77.24%, PPV ¼ 47.06%,
NPV¼ 95.18%) are similar to the results reported in themedical
literature. Furthermore, an appropriate high sensitivity was
achieved in all three examined populations (i.e., overall popu-
lation, premenopausal women, and postmenopausal women).
Some studies show that, in women with a RMI of less than
25, only few women (usually with borderline ovarian tumors)
are misdiagnosed as having benign disease, which means that
almost all patients with a RMI of less than 25 have a benign
adnexal mass. Therefore, a RMI value of 25 appears to be a
suitable threshold for determining which women would benefit
from additional imaging. This was also confirmed in our study.
Considering women with a RMI greater than 250 as having
malignant disease resulted in just a couple of incorrect di-
agnoses. Therefore, it would seem reasonable for this group of
women to be managed in a cancer unit by gynecological
oncologist [10,13]. In our study, the recommended interme-
diate risk level of RMI 25 had higher sensitivity, which proved
its reliability as a cutoff level. Almost all women with a RMI
less than 25 had benign tumors. This was true for premeno-
pausal and postmenopausal women, and for the overall pop-
ulation. In our study, the level of 29 furthermore showed the
same sensitivity, but a somewhat higher specificity than did the
RMI cutoff of 25. On the other hand, the recommended cutoff
level for high risk (i.e., a RMI of 250) was less accurate. A
Table 3
Sensitivity and specificity at different cutoff levels of the RMI.













25 94.1 27.4 91.7 32.2 95.1 9.8
250 72.9 86.9 54.2 88.3 80.3 79.73
RMI ¼ risk of malignancy index.
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the group of women with an intermediate risk (i.e., a RMI
between 25 and 250). We advise that every finding of RMI
above 100 should alert our attention. All such cases need
further diagnostic evaluation.
The minimum PPV set by most epidemiologists to support a
screening test is 10% [3]. Because of the low prevalence of
ovarian cancer (40 cases/year per 100,000women over the age of
50 years), a screening test must have both a high sensitivity and a
high specificity to be clinically useful. It is estimated that a
screening test for ovarian cancer would require a sensitivity of at
least 75% and a specificity of more than 99.6% to achieve a PPV
of 10%. In our study, the PPV of the RMI was 47.6% for the
overall population, 28.89% for premenopausal women, and
63.92% for postmenopausal women. This is even higher than
recommended. These findings confirm the previous RMI value
for postmenopausal patients, with recommendation for its
implementation for premenopausalwomenwith adnexalmasses.
Some studies report that the specificity of RMI is lower in
younger women [14]. On the other hand, in our study, the RMI
was reliable in 84.6% of both premenopausal and post-
menopausal patients with adnexal masses. Moreover, the RMI
is precise for 81.1% of postmenopausal women. These results
are in agreement with the usual literature data that indicates
that the RMI should be only used for postmenopausal women
since it can show its full predictive power only in that popu-
lation [3]. However, the RMI in our study also explained 77%
of premenopausal cases. This is similar to some other in-
vestigations [14e16]. Therefore, the RMI can be accurately
used for premenopausal women, which we recommend.
In conclusion, it can be said that there were no significant
differences between women with malignant and borderlineTable 4
Number of positive and negative findings and the sensitivity, specificity,








True positive findings (no.) 88 26 62
False positive findings (no.) 99 64 35
False negative findings (no.) 17 5 12
True negative findings (no.) 336 261 75
Sensitivity (%) 83.81 83.87 83.78
Specificity (%) 77.24 80.31 68.18
Positive predictive value (%) 47.06 28.89 63.92
Negative predictive value (%) 95.18 98.12 74.71
RMI ¼ risk of malignancy index.tumors in regard to their age. However, women with benign
tumors were younger. A high risk for malignancy was more
frequent in postmenopausal women, whereas low and inter-
mediate risks were more usual in premenopausal women. The
RMI was reliable in 84.6% of cases in the overall population
of premenopausal and postmenopausal patients; in 77% of
premenopausal patients, and in 81.1% of postmenopausal
patients. The sensitivity of the RMI was 83.81% in the overall
population; 83.87% for premenopausal women; and 83.78%
for postmenopausal women. It consequently can be concluded
that the RMI is a reliable factor for differentiating benign from
malignant adnexal masses in premenopausal and post-
menopausal patients. Therefore, we recommend using the
RMI during the preoperative triage of adnexal masses in
premenopausal and postmenopausal patients.Acknowledgments
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